Skip to main content
Log in

43. Jahrestagung der American Society of Clinical Oncology 2007

Chicago, 1.–5. Juni, 2007

43rd Annual Meeting of the American Society of Clinical Oncology 2007

Chicago, 1–5 June 2007

  • Aktuelle Onkologie
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Llovet J et al. (2007) Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Proc Am Clin Oncol 25: 1s; Abstract 1

    Google Scholar 

  2. Powell BL et al. (2007) Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL). Proc Am Clin Oncol 25: 1s; Abstract 2

    Google Scholar 

  3. Nordlinger B et al. (2007) First results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX-4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc Am Clin Oncol 25: 2s; Abstract LBA5

    Google Scholar 

  4. Slotman B et al. (2007) A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993). Proc Am Clin Oncol 25: 2s; Abstract 4

    Google Scholar 

  5. Escudier B et al. (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. Proc Am Clin Oncol: Abstract 3

    Google Scholar 

  6. DeMatteo et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG Z9001. Proc Am Clin Oncol: Abstract 10079

    Google Scholar 

  7. Dewar JA, Haviland JS, Agrawal RK et al. (2007) Hypofractionation for early breast cancer: First results of the UK standardisation of breast radiotherapy (START) trials. Proc Am Clin Oncol 25: Part II, 964s; Abstract LBA518

    Google Scholar 

  8. Rastogi P et al. (2007) Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H). Proc Am Clin Oncol 25: Part II, 964s; Abstract LBA513

    Google Scholar 

  9. Van Cutsem E et al. (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (CRC): the CRYSTAL trial. Proc Am Clin Oncol 25: 64s; Abstrac 4000

    Google Scholar 

  10. Vermorken J et al. (2007) Erbitux extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy – Results of a randomized phase III (Extreme) study. Proc Am Clin Oncol 25: 64s; Abstract 6091

    Google Scholar 

Download references

Danksagung

Für die Unterstützung bei der Aufarbeitung dieser ASCO-Highlights danke ich Herrn Professor W. Wagner, Osnabrück

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Reisekostenübernahme durch Novartis Pharma.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Junker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Junker, A. 43. Jahrestagung der American Society of Clinical Oncology 2007. Onkologe 13, 851–857 (2007). https://doi.org/10.1007/s00761-007-1245-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-007-1245-5

Navigation